Matsumoto Natsumi

Researcher

基本情報

Profile and Settings

• 氏名

  Matsumoto Natsumi

Affiliation

• Cancer Genome and Pharmacotherapy, Senior Lecturer

Location

• Hatanodai Campus

Degree

• Doctor of Pharmaceutical Science, Showa University, Sep. 2020

Achievements

Published Papers

• ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in Japanese subjects, Matsumoto N, Oishi A, Yoshino S, Masuo Y, Kubota Y, Ishida H, Shimada K, Kato Y, Fujita KI, Br J Clin Pharmacol, Jun. 2025, Peer-reviewed
• Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction, Arakawa H, Ishida N, Nakatsuji T, Matsumoto N, Imamura R, Shengyu D, Araya K, Horike S, Tanaka-Yachi R, Kasahara M, Yoshioka T, Sumida Y, Ohmiya H, Daikoku T, Wakayama T, Nakamura K, Fujita K, Kato Y, Biochem. Pharmacol., May 2024, Peer-reviewed
• Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reactions and survival of regorafenib in Japanese patients with colorectal cancer, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, Cancer Chemotherapy and Pharmacology, 2024, Peer-reviewed
• Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer., Nakayama Hana;Ishida Hiroo;Iidaka Masanori;Kato Shoko;Nakatani Kei;Nakayama Akihiro;Noguchi Toshihiro;Nishihara Shigetoshi;Oikawa Shu;Usami Tomono;Mitsui Yuta;Ishii Y U;Toshima Hirokazu;Kobayashi Kouji;Murase Remi;Matsumoto Natsumi;Suzuki Kosuke;Shimada Ken;Yoshida Hitoshi;Fujita Ken-Ichi, Anticancer research, 44(11), 2024, Peer-reviewed
• A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer., Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, Cancer Chemother. Pharmacol., 92(6):465 - 474, Dec. 2023, Peer-reviewed, DOI:10.1007/s00280-023-04584-x
• Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer., Fujita Ken-Ichi;Matsumoto Natsumi;Murase Remi;Takeshima Kosuke;Ishida Hiroo;Kubota Yutaro, Clinical and translational science, 16(10):1741 - 1747, Oct. 2023, Peer-reviewed, DOI:10.1111/cts.13589
• Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer. A prospective study., Yuta Nio; Hiroo Ishida; Natsumi Matsumoto; Sojiro Kusumoto; Yutaro Kubota; Takuya Tsunoda; Yasutsuna Sasaki; Ken‐ichi Fujita, BMC Pulm. Med., 22(1):454, Nov. 2022, Peer-reviewed, DOI:10.1186/s12890-022-02249-8
• Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer., Jun Arai; Yumi Otoyama; Ken-Ichi Fujita; Kaku Goto; Masayuki Tojo; Atsushi Katagiri; Hisako Nozawa; Yutaro Kubota; Takehiro Takahashi; Hiroo Ishida; Takuya Tsunoda; Natsumi Matsumoto; Keita Ogawa; Ryo Nakagawa; Ryosuke Muroyama; Naoya Kato; Hitoshi Yoshida, BMC Cancer, 22(1):428, Apr. 2022, Peer-reviewed, DOI:10.1186/s12885-022-09512-5
• Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 88(3):543 - 553, Jun. 2021, Peer-reviewed
• 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients., Yusuke Masuo; Ken-Ichi Fujita; Kenji Mishiro; Natsumi Seba; Tatsuya Kogi; Hidenori Okumura; Natsumi Matsumoto; Munetaka Kunishima; Yukio Kato, Drug Metab. Pharmacokinet, Dec. 2020, Peer-reviewed
• Correlation between the metabolic conversion of a capecitabine metabolite, 5′-deoxy-5-fluorocytidine, and creatinine clearance, INAISHI Takahiro;FUJITA Ken-ichi;MATSUMOTO Natsumi;SHIMOKATA Tomoya;MAEDA Osamu;KIKUMORI Toyone;HATTORI Norifumi;NAKAYAMA Goro;ANDO Yuichi, In Vivo, 34(6):3539 - 3544, Nov. 2020, Peer-reviewed
• Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, Jun. 2020, Peer-reviewed
• Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure, FUJITA Ken-ichi;MATSUMOTO Natsumi;ISHIDA Hiroo;KUBOTA Yutaro;IWAI Shinichi;SHIBANUMA Motoko;KATO Yukio, Curr Drug Metab, 20(5):361 - 376, Mar. 2019, Peer-reviewed
• Central versus peripheral impact of estradiol on the impaired glucose metabolism in ovariectomized mice on a high-fat diet., Rika Yonezawa; Tsutomu Wada; Natsumi Matsumoto; Mayuko Morita; Kanae Sawakawa; Yoko Ishii; Masakiyo Sasahara; Hiroshi Tsuneki; Shigeru Saito; Toshiyasu Sasaoka, American journal of physiology. Endocrinology and metabolism, 303(4):E445-56, Aug. 2012, Peer-reviewed

Presentations

• Association of polymorphisms in genes encoding immune response-related factors and regorafenib-induced erythema multiforme in patients with advanced colorectal cancer, Geonwoo Lee, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida and Ken-ichi Fujita, 日本薬学会第145年会, 28 Mar. 2025, 日本薬学会, 福岡
• The Improvement and Effect of Coaching Training Aimed at Enhancing the Teaching Skills of Young Instructors in Hospital Practice at Showa University, Natsumi Matsumoto, Yuka Kashiwabara, Ryo Yonezawa, Akane Hoshi, Akitoshi Takuma, Koji Karasawa, Toshihiro Tanioka, Iori Taki, Hidetsugu Nakagawa, Takeshi Uchikura, Mari Kogo, Katsumi Tanaka, 日本薬学会第145年会, 28 Mar. 2025
• Effect of base-line plasma albumin and unbound plasma level of lenvatinib in patients with hepatocellular carcinoma, 鈴木康介、音山裕美、中島陽子、杉浦育也、冨士貴弘、野村英里佳、市川雪、下間祐、打越学、坂木理、水戸守智香、増尾友佑、早野桃花、松本奈都美、村瀬礼美、加藤将夫、吉田仁、藤田健一, 2025 the Japanese Society of Medical Oncology Annual Meeting, 07 Mar. 2025, Japanese Society of Medical Oncology, 神戸コンベンションセンター
• A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics, Kengo Omata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida3 Ken Shimada, and Ken-ichi Fujita, 2025 the Japanese Society of Medical Oncology Annual Meeting, 06 Mar. 2025
• Association between ABCC2 -24C>T and nab-paclitaxel-induced peripheral neuropathy in Japanese patients with pancreatic cancer, Hana Nakayama,Hiroo Ishida, Masanori Iidaka, Shoko Kato, Kei Nakatani, Akihiro Nakayama, Toshihiro Noguchi, Shigetoshi Nishihara, Shu Oikawa, Tomono Usami, Yuta Mitsui, Yu Ishii, Hirokazu Toshima, Kouji Kobayashi, Remi Murase, Natsumi Matsumoto, Kosuke Suzuki, Ken Shimada, Hitoshi Yoshida, Ken-ichi Fujita, 2025 the Japanese Society Medical Oncology annual Meeting, 06 Mar. 2025, 日本臨床腫瘍学会, 神戸
• Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
• Effect of VEGFA and CCL4L2 variants on hand-foot skin reaction and survival of regorafenib in Japanese patients with CRC, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, 2024 the Japanese Society Medical Oncology Annual Meeting, 22 Feb. 2024, Hirogi Iwata, Nagoya Congress Center
• Regulation of drug-metabolizing enzymes activity by ABCC4 expression in liver., Ikeda Y, Masuo Y, Oishi A, Matsumoto N, Fujita KI, Kato Y, The 38th Annual Meeting of Japanese Society for the Study of Xenobiotics, 28 Sep. 2023
• 若手薬剤師の指導力向上を目的としたコーチング研修の導入とアンケートによる評価．日本薬学会第143年会, 小池佑果，嶋村弘史，柏原由佳，市倉大輔，玉造竜郎，米澤龍，唐沢浩二，松本奈都美，滝伊織，百賢二，向後麻里，田中克己，中村明弘, 日本薬学会第143年会, 28 Mar. 2023
• A polymorphisms in ABCA2 is associated with pharmacokinetics and toxicity of capecitabine in colorectal cancer patients, Yukitaka Shibata, Natsumi Matsumoto, Yutaro Kubota, Takuya Tsunoda, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, The 20th Japanese Society of Medical Oncology annual meeting, 16 Mar. 2023, Fukuoka
• Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients, Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita, 2023 the Japanese Society of Medical Oncology Annual Meeting. The 20th Anniversary Meeting, 16 Mar. 2023, Japanese Society of Medical Oncology, Fukuoka International Congress Center/ Marine Messe
• レンバチニブ投与患者血漿検体のメタボロミクス解析による薬効バイオマーカー探索, 水戸守智香、 増尾友佑、 荒井潤、 松本奈都美、 鈴木康介、 吉田仁、藤田健一、 加藤将夫, 第43回日本臨床薬理学会学術総会, 30 Nov. 2022
• Effect of genetic mutation of the endoplasmic reticulum membrane transporter OAT2 on the pharmacokinetics of the anticancer drug capecitabine., 石田尚輝、荒川大、松本奈都美、藤田健一、加藤 将夫, The 37th Annual Meeting of Japanese Society for the Study of Xenobiotics, 08 Nov. 2022
• Estimation of pharmacokinetic parameter alternation for capecitabine and its metabolites in colorectal cancer patients with ABCC4 genetic polymorphism, Ayano Oishi, Yusuke Masuo, Natsumi Matsumoto, Ken-ichi Fujita, Yukio Kato, The 37th Annual Meeting of Japanese Society for the Study of Xenobiotics, 08 Nov. 2022
• Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with colorectal cancer., TAKESHIMA Kousuke;MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;TSUNODA Takuya;SASAKI Yasutsuna;FUJITA Ken-ichi, 123rd American Society for Clinical Pharmacology and Therapeutics annual meeting (accepted)., 16 Mar. 2022, Web
• 改訂薬学教育モデル・コアカリキュラムにおける実務実習で関わるべき代表的な8疾患の実習実施状況調査, 滝伊織，唐沢浩二，松本奈都美，田島正教，福村基徳，百賢二，黒沢雅広，山本仁美，松林智子，熊木良太，斎藤清美，柴田佳太，谷岡利裕，岸本桂子，小林靖奈，福原潔，佐々木忠徳，原俊太郎，向後麻里，中村明弘, 日本薬学会第142年会, Mar. 2022
• Regorafenib-induced erythema multiforme is associated with HLA-C*01:02 and HLA-B*46:01 in Japanese cancer patients, 松本　奈都美;竹島　功高;久保田　祐太郎;石田　博雄;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 18 Feb. 2022, 京都＋Web開催
• Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
• Construction of physiologically based pharmacokinetic model of capecitabine and its metabolites in colorectal cancer patients with genetic polymorphism in ABC transporter gene., OISHI Ayano;MATSUMOTO Natsumi;FUJITA Ken-ichi;KATO Yukio, 日本薬物動態学会 第36回年会, 19 Nov. 2021, Web Meeting
• Capecitabineの加水分解反応における小胞体膜輸送体OAT2の役割, 石田　尚輝;荒川　大;松本　奈都美;藤田　健一;加藤　将夫, 日本薬剤学会第36年会, 13 May 2021, オンライン開催
• SN-38の体内動態とOATP1B1の機能:重篤な腎機能障害のない患者において, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第18回日本臨床腫瘍学会学術集会 (JSMO2021), 18 Feb. 2021, オンデマンド配信
• 抗悪性腫瘍薬イリノテカンの活性代謝物SN-38の体内動態とOATP1B1輸送活性との関連, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第41回日本臨床薬理学会学術総会, 05 Dec. 2020, 福岡およびWeb会場
• ABCC4遺伝子多型のカペシタビンと代謝物の体内動態への影響, 松本　奈都美;久保田　祐太郎;角田　卓也;石田　博雄;嶋田　顕;増尾　友佑;加藤　将夫;藤田　健一, 第41回日本臨床薬理学会学術総会, 03 Dec. 2020, 福岡およびWeb会場
• No effects of variants in carboxylesterase 1 gene on pharmacokinetics of capecitabine and its metabolites, 松本　奈都美;久保田　祐太郎;石田　博雄;関戸　匡恵;柴沼　質子;嶋田　顕;藤田　健一, 日本薬学会第140年会, 26 Mar. 2020, Web公開

Books etc

• 患者に合わせた処方意図がわかる！同効薬・類似薬のトリセツ, 鎮痛薬, 松本奈都美, 188-215, メジカルビュー社, Mar. 2023, Peer-reviewed